|
**Overview**: Urea Cycle Disorder Panel**Introduction**: The Urea Cycle Disorder Panel is a diagnostic tool designed for urea cycle disorder screening using serum samples. In India, urea cycle disorders (UCDs) are rare but severe inborn errors (prevalence ~1 in 35,000 births), with ornithine transcarbamylase deficiency (OTC) most common, causing neonatal hyperammonemia, coma, or late-onset encephalopathy. High morbidity from underdiagnosis in rural/low-SES neonates with vomiting, lethargy, or seizures, limited metabolic labs, delayed ammonia-lowering therapy/diet leading to brain damage or death. Per metabolic practices aligned with ICMR, Indian Society for Inborn Errors of Metabolism, and Newborn Screening guidelines, the test employs spectrophotometry/PCR for ammonia, citrulline, arginine, ornithine, argininosuccinic acid, urea, and mutations (CPS1, OTC, ASS1) over 3â€"5 days with high accuracy, valuable for confirming hyperammonemia and enzyme defects. This diagnostic falls under metabolic screening and targets neonates/infants with encephalopathy or family history, addressing accurate detection to guide dialysis, nitrogen scavengers, or liver transplant. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early UCD profiling and reducing neonatal mortality. Its serum-based approach ensures reliable metabolite/genetic assessment.**Other Names**: Urea Cycle Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/molecular diagnostics, compliant with 2025 standards.**Historical Milestone**: Urea cycle metabolite/genetic panel standard in IEM diagnosis; in India, expanding in metabolic centers.**Purpose**: The test assesses 9 parameters including ammonia to guide UCD screening, detect hyperammonemia/mutations, inform acute/chronic management.**Test Parameters**: 1. Ammonia, 2. Citrulline, 3. Arginine, 4. Ornithine, 5. Argininosuccinic Acid, 6. Urea, 7. CPS1 Mutation, 8. OTC Mutation, 9. ASS1 Mutation.**Pretest Condition**: No fasting required; patients should have encephalopathy or family history.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve metabolite integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients/parents should provide details on neonatal vomiting, seizures.**Consent**: Written informed consent (parental) is required, detailing the test's purpose, potential risks of undetected UCD including coma/death, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry/PCR by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 3â€"5 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Hyperammonemia + abnormal citrulline/arginine indicates UCD; mutation confirms specific defect, necessitating specialist input.**Specialist Consultation**: Pediatric metabolic specialists should be consulted for management.**Additional Supporting Tests**: Plasma amino acids, urine orotic acid for confirmation.**Test Limitations**: Requires urgent ammonia measurement; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, IEM Studies India 2023. |
